SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Lindgren Hanna)
 

Search: WFRF:(Lindgren Hanna) > (2010-2014) > Chapter 22 - Rodent...

Chapter 22 - Rodent Models of Treatment-Related Complications in Parkinson Disease

Francardo, Veronica (author)
Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
Iderberg, Hanna (author)
Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
Lindgren, Hanna (author)
Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
show more...
Cenci Nilsson, Angela (author)
Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
LeDoux, Mark S. (editor)
show less...
 (creator_code:org_t)
2nd
2014
2014
English 14 s.
In: Movement Disorders : Genetics and Models - Genetics and Models. - 9780124051959 ; , s. 373-386
  • Book chapter (peer-reviewed)
Abstract Subject headings
Close  
  • Dopamine replacement therapy effectively relieves the typical motor features of Parkinson disease (PD), but it can cause complications that limit its utility. Dyskinesia (abnormal involuntary movements) and motor fluctuations (abrupt changes in the patients' motor status) occur in most PD patients after a few years of 3,4-dihydroxyphenyl-. l-alanine (l-DOPA) pharmacotherapy. Animal models reproducing these motor complications can be obtained in mice and rats if the nigrostriatal dopamine pathway is severely damaged. Within the large arsenal of neurotoxic and genetic models of PD, rodents with unilateral 6-hydroxydopamine lesions have the best characteristics for the sake of modeling l-DOPA-induced dyskinesia. When treated chronically with high doses of l-DOPA, these rodent models may also display motor response alterations reminiscent of the wearing-off fluctuations that occur in PD patients. Because of research performed on these animal models, our understanding of the molecular and biochemical mechanisms of l-DOPA-induced dyskinesia has made great advances, and several pharmacological approaches to treatment have been recently identified and successfully tested in proof-of-concept trials in PD patients. It is now well recognized that dopaminergic therapies for PD also cause nonmotor fluctuations (e.g., abrupt changes in mood and cognitive performance) and impulse control disorders. Valid rodent models of these nonmotor complications need to be developed as an important tool for basic and translational research on the cognitive and psychiatric features of PD.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Keyword

6-OHDA
Abnormal involuntary movements (AIMs)
L-DOPA
L-DOPA-induced dyskinesia
Nonmotor complications
Parkinson disease
Rodent models
Treatment-related complications

Publication and Content Type

kap (subject category)
ref (subject category)

Find in a library

To the university's database

Find more in SwePub

By the author/editor
Francardo, Veron ...
Iderberg, Hanna
Lindgren, Hanna
Cenci Nilsson, A ...
LeDoux, Mark S.
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
and Neurosciences
Articles in the publication
Movement Disorde ...
By the university
Lund University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view